http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

risedronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis 1 1 treatment to increase bone mass in men with osteoporosis 1 2 treatment and prevention of glucocorticoid induced osteoporosis 1 3 treatment of paget s disease 1 4 limitations of use optimal duration of use has not been determined for patients at low risk for fracture consider drug discontinuation after 3 to 5 years of use 1 5 risedronate sodium tablets usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis risedronate sodium tablets usp reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis related fractures see clinical studies 14 1 14 2 risedronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis risedronate sodium tablets usp are indicated for the treatment and prevention of glucocorticoid induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment daily dosage of greater than or equal to 7 5 mg of prednisone or equivalent for chronic diseases patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d risedronate sodium tablets usp are indicated for treatment of paget s disease of bone in men and women the optimal duration of use has not been determined the safety and effectiveness of risedronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of three years duration all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_5408 DOID_5408

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00884 drugbank:DB00884

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-13T11:21:24.381Z

http://purl.org/np/RAEjagJ0BR... RAEjagJ0BR

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-13T11:21:24.381Z